While Trilaciclib is specifically indicated to mitigate chemotherapy-induced myelosuppression, the remaining four agents are predominantly utilized in combination with endocrine therapies for HR+/HER2- breast cancer, reflecting their established role as first-line treatments in this molecular subtype. Here, ERBB2 is linked to breast cancer.